BSN Medical GmbH
Latest From BSN Medical GmbH
Acelity has agreed to acquire Crawford Healthcare for an undisclosed price to expand its wound care portfolio. Crawford's wound-dressing portfolio includes the KerraMax Care, KerraFoam, and KerraCel brands, complementing Acelity's advanced wound dressing line-up, which includes the Promogran Prisma Matrix collagen dressing, the Tielle dressings, and Adaptic dressings. The deal also includes Crawford's research and development and manufacturing facilities in Chesire, UK.
Randomized trial results show pharmacomechanical, catheter-directed thrombolysis does not reduce the development of post-thrombotic syndrome in patients treated for deep-vein thrombosis. The study’s investigator suggests limiting the procedure to treatment of large iliofemoral blood clots causing major symptoms in patients who are at low risk of bleeding.
Medtech companies raised $2.4 billion in the fourth quarter, the second-strongest of the year; Q4 device M&A deals totaled $9 billion in value, led by Allergan's $2.9 billion buy of Acelity's LifeCell division. Diagnostics financings finished out the year at $721 million, an increase over the previous quarter and 2016's second-highest quarter, but diagnostics M&A activity was the lowest of the year at $87 million, with only two completed acquisitions.
Start-ups raised $2.41 billion in Q4 2015. Biopharma companies penned 29 alliances; seven acquisitions were signed in the biopharma and diagnostics industries.
- Rehabilitation Equipment and Devices
- Therapeutic Areas
- Musculoskeletal & Connective Tissue Disorders
- Wound Healing & Tissue Repair
- BSN Medical GMBH & Co. KG
- Western Europe
- Parent & Subsidiaries
- BSN Medical GmbH
- Senior Management
- Steve Brown, CFO
- Contact Info
BSN Medical GmbH
Phone: (49) 40 4909 909
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.